VistaGen Therapeutics, Inc. (VTGN) News
Filter VTGN News Items
VTGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VTGN News Highlights
- For VTGN, its 30 day story count is now at 2.
- Over the past 7 days, the trend for VTGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about VTGN are CNS and TSE.
Latest VTGN News From Around the Web
Below are the latest news stories about VISTAGEN THERAPEUTICS INC that investors may wish to consider to help them evaluate VTGN as an investment opportunity.
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023Explore the potential of the best short-squeeze stocks to buy now as companies attempt to prove pessimistic traders wrong. |
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric DisorderSOUTH SAN FRANCISCO, Calif., September 12, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that PH80, one of the Company’s five investigational neuroactive nasal sprays, demonstrated statistically significant improvement versus placebo in an exploratory Phase 2A study for acute management of the symptoms of p |
Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagen’s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in JapanSOUTH SAN FRANCISCO, Calif. & TOKYO, September 05, 2023--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, and Fuji Pharma Co., Ltd. ("Fuji") (TSE: 4554), a pharmaceutical company specializing in development, manufacture and marketing in the fields of women’s healthcare and acute medical care, today announced they have entered into a tim |
Vistagen Appoints Cindy Anderson as Chief Financial OfficerSOUTH SAN FRANCISCO, Calif., August 22, 2023--Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced the appointment of Cindy Anderson as Chief Financial Officer (CFO), effective August 21, 2023. Ms. Anderson will succeed Jerrold Dotson, whose planned retirement was announced in July of this year. |
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call TranscriptVistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 First Quarter Corporate Update Conference Call. [Operator Instructions] And as a reminder, this conference is being recorded, Thursday, August 10, 2023. I would now like to turn the conference over to Mark […] |
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More NewsRegulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders should watch on Thursday morning! |
Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial ResultsSOUTH SAN FRANCISCO, Calif., August 10, 2023--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2024 first quarter ended June 30, 2023. |
COMMODORE CAPITAL LP Acquires New Stake in Vistagen Therapeutics IncFirm real-time pick highlight |
AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety DisorderAffaMed Therapeutics ("AffaMed") announced today that its partner Vistagen Therapeutics ('Vistagen' - NASDAQ: VTGN), a clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, reported positive top-line results from its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol (PH94B) nasal spray in adults diagnosed with social anxiety disor |